This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.

Head and Neck Cancer

Whitney Lewis, PharmD, BCOP
The University of Texas MD Anderson Cancer Center

Data on currently available immunotherapeutic agents for recurrent/metastatic head and neck squamous cell carcinoma point to a new standard of care with immune checkpoint inhibitors. Listen to the latest results comparing these inhibitors to chemotherapy, and the symptoms, workup, diagnosis, and management of a head and neck squamous cell carcinoma patient with hypophysitis.


Download Slides


These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.